GENETICS AND PROSTATE CANCER

VistaSeq® Germline Testing

labcorp

GENETICS AND PROSTATE CANCER

VistaSeq® Germline Testing

Hereditary cancer syndromes account for approximately 5-10% of all prostate cancers and are caused by inherited mutations (pathogenic variations) in certain genes.[1] These inherited disorders increase the risk of developing cancer, often at an earlier age than expected. BRCA-related breast and ovarian cancer syndrome and Lynch syndrome are two syndromes known to be associated with a history of prostate cancer. In addition to susceptibility to prostate cancer, each of these conditions increase a person's risk for other cancers.

The National Comprehensive Cancer Network Guidelines (NCCN Guidelines for Patients®) and recommendations

Patients diagnosed with Grade Group (GG) 1-3 prostate cancers and a suspicious family history should undergo germline testing, and those with GG 4 and 5 prostate cancers should be tested as well.[2]

Patients who meet the criteria for hereditary cancer risk assessment should undergo germline genetic testing.[3]

Why Test?

- It can identify patients with genetic mutations who are more likely than the general population to develop certain types of cancer.
- Testing enables personalized medical management based on the patient's prostate cancer risk, as well as screening younger patients earlier and more frequently.[4]
- Testing for prostate cancer patients may provide specific information about the patient's risk of recurrence.
- In patients with prostate cancer, genetic testing can enable targeted medical and surgical treatment options.[5]
- Encourages family members to undergo targeted genetic testing.

VistaSeq Prostate Panel

How Labcorp Can Help

Labcorp now offers a new VistaSeq panel for prostate cancer that identifies the genes ATM, BRCA1, BRCA2, CHEK2, HOXB13 (no CNVs), MLH1, MSH2, MSH6, PALB2, and PMS2.

The NCCN Guidelines note that multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.[6]

Every patient comes from a different background with a unique personal and family medical history. When evaluating a patient for hereditary cancer risk, the better test to choose is one that matches the needs of the patient based on the complete medical history.

Consider VistaSeq panel testing for your patients who meet NCCN hereditary cancer risk assessment criteria. This includes a personal or family history of one or more of the following[6]:

- A previously identified germline mutation in the family
- Metastatic or intraductal prostate cancer
- Any NCCN prostate cancer risk group and Ashkenazi Jewish ancestry
- Prostate cancer at any age and a close relative with breast cancer diagnosed ≤ 50 or ovarian cancer at any age.
- Three or more cancers such as prostate or breast cancer at any age
- Male breast cancer
- Exocrine pancreatic cancer

Broadening Your Patients' Options

VistaSeq hereditary cancer panels are designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.

GENETICS AND PROSTATE CANCER

Labcorp Services

Labcorp provides expertise to your practice through genetic counseling services tailored to you and your patients.

With more than 25 years of experience, Labcorp offers the largest national commercial network of genetic counselors. We provide a broad range of counseling services, including hereditary cancer care.

Our genetic counselors are available to support you in managing patients at risk for a hereditary cancer syndrome by explaining appropriate genetic testing options, discussing the implications of test results, and helping you and your patients make thoughtful genetic health care decisions.

Test/Panel Name	Test No.
VistaSeq® Prostate Panel	483555
VistaSeq® Hereditary Cancer Panel	481220
VistaSeq® without *BRCA1* and *BRCA2* genes	481240
VistaSeq® Breast Cancer Panel	481319
VistaSeq® High/Moderate Risk Breast Cancer Panel	481452
VistaSeq® GYN Cancer Panel	481330
VistaSeq® Breast and GYN Cancer Panel	481341
Mutation-specific Sequencing	640/641

Specimen requirements:
10 mL whole blood lavender-top (EDTA) tube
OR
2 mL saliva Oragene®•Dx saliva collection kit

Comprehensive genetic counseling includes:

- Genetic risk assessment, including a review of the patient's personal and family medical histories and genetic test results
- Patient education about genetic risk factors and appropriate testing options
- Patient information and support for informed decision-making
- Coordinated patient care to assist you in offering the right test at the right time to the right patient

Call 855-GC-CALLS (855-422-2557) to learn more about our exceptional services or visit:
integratedgenetics.com/genetic-counseling

Additional Benefits:

Rapid results
Turnaround time of 2-3 weeks

Extensive managed care contracts
Help patients maximize their benefits

Convenient blood draws
Labcorp has a nationwide network of patient service centers, allowing easy access to sample collection. Visit www.Labcorp.com to find the nearest location.

References
1. The Genetics of Cancer. National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics. Accessed July 6, 2021.
2. Prostate Cancer. NCCN Guidelines for Patients®, Version 2.2021.
3. Prostate Cancer: Early Stage Detection. NCCN Guidelines for Patients®, Version 2.2021. Available at: https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf. Accessed July 5, 2021.
4. Genetic Testing for Prostate Cancer: What You Should Know. Urology Care Foundation. Available at: https://www.urologyhealth.org/healthy-living/urologyhealth-extra/magazine-archives/fall-2018/genetic-testing-for-prostate-cancer-what-you-should-know. Accessed July 6, 2021.
5. Targeted Therapy for Prostate Cancer. American Cancer Society. Available at: https://www.cancer.org/cancer/prostate-cancer/treating/targeted-therapy.html. Accessed July 6, 2021.
6. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Guidelines, Version 2.2021. Available at: https://www2.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf. Accessed January 3, 2020.

To learn more, visit **Labcorp.com**
or contact your Labcorp representative.

labcorp